To confirm that the decreased levels of CAMK2A were specific to MS rather than to non-specific neuroinflammation, a population of 10 inflammatory neurological controls identified from the Ottawa MS biobank were used as a comparison (Table 1). This evidence concerns the gene CAMK2A and myeloid sarcoma.